Massachusetts Lawmakers Push Forward Psychedelic Therapy Programs

BOSTON – Massachusetts lawmakers have advanced legislation that would set up pilot programs for regulated psychedelic therapy, with one measure clearing a key committee in September 2025 and related proposals still under review.

The Senate Bill S.1400, sponsored by Sen. Cindy Friedman, won favorable approval from the Joint Committee on Mental Health, Substance Use and Recovery. It directs the Department of Public Health to license up to three specialized mental health clinics for supervised administration of psychedelic materials to treat conditions like depression, anxiety, PTSD, and substance use disorders.

Clinics would operate under strict rules set by the department, including on-site delivery by multidisciplinary teams, patient screening and ongoing data tracking on outcomes. The measure bars participation by any organization linked to Cannabis businesses, psychedelic drug developers or pharmaceutical companies to keep the focus on independent mental health care.

A companion House Bill H.4200, sponsored by Rep. James O’Day, carries the same title and purpose and remains under committee consideration, with its reporting deadline extended to March 18, 2026. A separate proposal, H.2203, sponsored by Rep. Marjorie Decker, would create a psilocybin-specific pilot for adults with PTSD and other listed conditions; its reporting date was also extended to March 18, 2026.

The committee action on S.1400 drew no opposition and followed earlier local decriminalization measures in several Massachusetts cities. It also comes after voters rejected a broader statewide ballot question on psychedelics in 2024 and after the governor signed a separate measure creating a working group to study benefits for veterans. As of mid-March 2026, S.1400 sits with the Senate Committee on Ways and Means after clearing health care financing review.

These bills reflect a data-first strategy that prioritizes oversight and outcome reporting. With limited sites and clear conflict-of-interest rules, any approved programs would generate evidence that could guide future decisions on access and safety standards, much like early medical Cannabis pilots in other states. As the measures move forward in the 194th General Court, the emphasis remains on building a record of results rather than rapid expansion.